<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344303</url>
  </required_header>
  <id_info>
    <org_study_id>CP130-1008</org_study_id>
    <nct_id>NCT02344303</nct_id>
  </id_info>
  <brief_title>Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals</brief_title>
  <official_title>A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trevena Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trevena Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the electrocardiogram effects of TRV130 relative to placebo at therapeutic and
      supratherapeutic doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Part A of the study will assess clinical safety data of TRV130

        -  Part B of the study will assess the effect of single dose TRV130 on QTc
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A - Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Prior to dose through 4 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B - Change from baseline in QTc</measure>
    <time_frame>Prior to dose through 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B - Pharmacodynamics - QTc</measure>
    <time_frame>Prior to dose through 24 hours</time_frame>
    <description>Including QTc, heart rate, PR interval, QRS interval, uncorrected QT interval, ECG morphology and correlation between the QTcF change from baseline and plasma concentrations of TRV130.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B - Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>Prior to dose through Follow-Up Visit</time_frame>
    <description>Adverse events reporting, clinical observations, 12- lead electrocardiograms, vital signs, respiratory rate, body temperature and safety laboratory tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A &amp; B - Pharmacokinetics - Cmax, tmax, AUC</measure>
    <time_frame>Prior to dose through 24 hours</time_frame>
    <description>Parameters will include (but not limited to): Cmax, tmax, AUC0-Ï„, z: (apparent terminal rate constant calculated from the regression analysis (slope) of the log-transformed measured concentrations on the terminal phase of the time)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed sequence, open label</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 way cross over, double blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRV130</intervention_name>
    <arm_group_label>Part A</arm_group_label>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and/or female subjects between the ages of 18 and 45 inclusive.

          -  Women must be either a) post-menopausal; b) surgically sterile; c) of child-bearing
             potential and practicing contraception or remaining sexually inactive.

          -  Men must be willing to abstain from sperm donation from the time of Screening through
             the Follow-up Visit and, if sexually active with a woman of child-bearing potential,
             must be protected by acceptable forms of effective contraception through the Follow-up
             Visit.

        Exclusion Criteria:

          -  Past or present diseases including, but not limited to, significant medical
             abnormalities including: psychiatric, neurologic, pulmonary, cardiac,
             gastrointestinal, genitourinary, renal, metabolic, endocrinologic or autoimmune
             disorders.

          -  Has previously participated in another TRV130 clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franck Skobieranda</last_name>
    <role>Study Director</role>
    <affiliation>Trevena Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>May 11, 2017</last_update_submitted>
  <last_update_submitted_qc>May 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

